Detalhe da pesquisa
1.
Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
PLoS Med
; 20(1): e1004156, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630477
2.
CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study.
BMC Med
; 20(1): 146, 2022 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379250
3.
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil.
Nat Commun
; 13(1): 4154, 2022 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35851597
4.
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study.
Lancet Reg Health Am
; 6: 100154, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34957437
5.
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
Nat Med
; 28(4): 838-843, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35140406
6.
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Lancet Infect Dis
; 22(6): 791-801, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35366959